Healthcare / Drug Manufacturers - Specialty & GenericBSE
$102.00
+0.33 (+0.32%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 17%
FCF escenarios
weak_data · normalized FCF $3.6M · quality 41.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
50/100
C
Piotroski
5/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$5.5B
P/E
85.7x
↑EV/EBITDA
14.5x
↑ROE
2.0%
↑Gross Margin
55.8%
↑Debt/Equity
0.42
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2023–2026 · 3 años de histórico normalizado
Revenue CAGR
-1.2%
FCF CAGR
+50.8%
FCF margin
1.4%
FCF / Net income
0.88x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $3.74B · net income $58.4M · FCF $51.5M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2026 | 2025 | 2024 | 2023 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $3.74B | $3.74B | $3.79B | $3.56B | $3.89B |
| Net Income | $58.4M | $58.4M | $121.7M | $172.5M | $244.3M |
| EBITDA | $413.9M | $413.9M | $495.1M | $454.8M | $577.9M |
| EPS | 1.19 | 1.19 | 2.50 | 3.54 | 5.01 |
| Gross Margin | 55.8% | 55.8% | 55.7% | 51.5% | 48.6% |
| Operating Margin | 2.7% | 2.7% | 6.2% | 7.5% | 9.1% |
| Net Margin | 1.6% | 1.6% | 3.2% | 4.9% | 6.3% |
| Balance Sheet | |||||
| Debt/Equity | 0.42 | 0.42 | 0.47 | 0.47 | 0.31 |
| Current Ratio | 1.45 | 1.45 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $51.5M | $51.5M | $3.6M | $-576.5M | $15.0M |
| Returns | |||||
| ROE | 2.0% | 2.0% | 4.8% | 7.2% | 12.2% |
| Valuation | |||||
| P/E | 85.71 | 85.71 | 33.92 | 28.55 | 15.22 |
| EV/EBITDA | 14.52 | 14.52 | 10.67 | 13.07 | 7.39 |
| P/B | 1.69 | 1.69 | 1.64 | 2.06 | 1.85 |
| Growth & Yield | |||||
| Revenue Growth | -1.2% | -1.2% | 6.6% | -8.5% | — |
| EPS Growth | -52.4% | -52.4% | -29.4% | -29.3% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
96.7%
EPS terminal req.
$9.05
Spread vs growth
-149.1%
5Y implied EPS CAGR
55.9%
EPS terminal req.
$10.95
Spread vs growth
-108.3%
10Y implied EPS CAGR
30.9%
EPS terminal req.
$17.64
Spread vs growth
-83.3%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+12.1%
Start / end P/E
36.5x → 86.0x
EPS bridge
2.50 → 1.19
Residual
-71.0%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.